查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601264

重组蛋白市场：依产品、服务、最终用户、功能分类 - 2025-2030 年全球预测

Recombinant Proteins Market by Product (Adhesion Molecules & Receptors, Growth Factors & Chemokines, Immune Response Proteins), Services (Cloning, Expression, Purification), End-User, Function - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年重组蛋白市值为50.5亿美元，预计到2024年将达到58亿美元，复合年增长率为14.51%，预计到2030年将达到130.4亿美元。

重组蛋白是透过重组DNA技术产生的人工蛋白，可在各种宿主系统中表达新蛋白。由于该技术能够高效地大规模生产高纯度蛋白质，因此对于治疗、诊断和研究应用极为重要。重组蛋白对于药物、疫苗和生技药品的开发以及农业和食品工业中用于改善植物和动物产品至关重要。最终用途包括医学研究、临床诊断和生物技术研究。重组蛋白市场受到成长要素的影响，例如反应器设计的进步、研发投资的增加以及需要创新疗法的慢性疾病盛行率的上升。这里蕴藏着丰富的商机，包括对个人化医疗和生物製药的需求不断增加，以及基因治疗和再生医学应用的扩大。市场扩张需要开拓新兴市场、利用具成本效益的生产技术并建立策略伙伴关係。然而，市场成长面临高生产成本、复杂的监管环境和智慧财产权问题的挑战。蛋白质表现和精製所涉及的技术复杂性也构成了障碍。推动创新需要专注于优化表达系统、开发用于储存和运输的新型稳定技术以及使用基于 CRISPR 的技术来增强蛋白质功能的研究。竞争考虑表明，这个市场竞争激烈，但发展迅速，其特征是持续的技术进步和向精准医疗的转变。为了在重组蛋白市场取得长期成功，公司需要跟上技术趋势和监管变化，并在经营模式中强调永续性和道德考量。

主要市场统计
基准年[2023] 50.5亿美元
预测年份 [2024] 58亿美元
预测年份 [2030] 130.4亿美元
复合年增长率（%） 14.51%

市场动态：揭示快速发展的重组蛋白市场的关键市场洞察

供需的动态交互作用正在改变重组蛋白市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 消费者越来越重视个人化医疗和蛋白质疗法
    • 老年人和儿童中感染疾病和慢性病的盛行率很高
    • 对生技药品和生物相似药蛋白质的需求不断增长
  • 市场限制因素
    • 对重组蛋白维护相关的高成本和时间消耗的担忧
  • 市场机会
    • 对生物标誌物发现的日益关注和对重组蛋白开发的快速投资
    • 重组蛋白在动物繁殖、饲料效率和健康方面的潜力不断增长
  • 市场挑战
    • 替代产品的可取得性和生产中的一些问题

波特五力：驾驭重组蛋白市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解重组蛋白市场的外部影响

外部宏观环境因素在塑造重组蛋白市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解重组蛋白市场的竞争格局

对重组蛋白市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵重组蛋白市场供应商绩效评估

FPNV定位矩阵是评估重组蛋白市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 消费者越来越重视个人化医疗和蛋白质疗法
      • 老年人和儿童感染疾病和慢性病盛行率高
      • 生物製药和生物相似药蛋白的需求快速成长
    • 抑制因素
      • 重组蛋白成本与维护时间问题
    • 机会
      • 对生物标誌物发现的更多关注和对重组蛋白开发的投资激增
      • 扩大重组蛋白在动物繁殖、饲料效率和健康方面的潜力
    • 任务
      • 替代产品的可用性和一些生产问题
  • 市场区隔分析
    • 产品：黏附分子和受体在研究中的重要用途
    • 服务：表达服务注重高产量和与目标蛋白质特性的兼容性
    • 最终用户：重组蛋白在製药和生物製药公司的广泛使用
    • 功能：重组蛋白在药物发现与开发的潜在需求
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章重组蛋白市场：副产品

  • 黏附分子和受体
  • 生长因子和趋化素
  • 免疫反应蛋白
  • 激酶蛋白
  • 膜蛋白
  • 重组代谢酶
  • 调节蛋白
  • 结构蛋白

第七章重组蛋白市场：依服务分类

  • 复製
  • 表达
  • 精製

第 8 章重组蛋白市场：依最终用户分类

  • 学术研究所
  • 合约研究组织和契约製造组织
  • 製药和生物製药公司

第 9 章重组蛋白市场：按功能

  • 诊断
  • 药物发现与开发
    • 生物製药
    • 细胞/基因治疗
    • 疫苗

第10章美洲重组蛋白市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太重组蛋白市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲重组蛋白市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • iTolerance 与 Northway Biotech 签署融合蛋白生产协议
    • Biovian 在芬兰製造工厂投资超过 5,000 万欧元
    • 富通生命科学公司收购 International 照护现场
    • Curia 利用 CHOZN 平台扩展细胞株开发服务
    • Future Fields 融资 1,120 万美元，扩大果蝇重组蛋白生产规模
    • 默克生物开发中心扩建，法国马蒂利亚克
    • Shenandoah Biotechnology 宣布扩大根据 cGMP 实践生产的 CTGrade 重组蛋白系列
    • FUJIFILM收购领先的重组蛋白製造商 Shenandoah Biotechnology
    • Thermo Fisher Scientific 完成对 Peprotech 的收购，进军重组蛋白领域

公司名单

  • Takara Bio Inc.
  • GeoVax Labs, Inc.
  • Takeda Pharmaceutical Company Limited
  • LenioBio GmbH
  • Sino Biological, Inc.
  • Sanofi SA
  • Bio-Rad Laboratories, Inc.
  • R&D Systems, Inc. by Bio-Techne Corporation
  • Proteos, Inc.
  • BPS Bioscience, Inc.
  • Proteintech Group, Inc.
  • BioLegend, Inc. by PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.
  • Miltenyi Biotec BV & Co. KG
  • Fortis Life Sciences LLC
  • Sartorius AG
  • Bristol-Myers Squibb Company
  • Creative BioMart Inc.
  • Biogen Inc.
  • Abnova Corporation
  • Hzymes Biotech
  • Merck KGaA
  • Novartis AG
  • Agilent Technologies, Inc.
  • Lonza Group AG
  • SK bioscience
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Bhat Bio-tech India Private Limited
  • GenScript Biotech Corporation
  • Marin Biologic Laboratories, Inc.
  • Meridian Bioscience, Inc. by SD Biosensor Inc.
  • ProMab Biotechnologies, Inc.
  • Abcam PLC
  • Laurus Labs Limited
  • Biologics International Corp
  • Croyez Bioscience Co., Ltd.
  • Enzo Life Sciences, Inc.
  • Selvita SA
Product Code: MRR-501246437434

The Recombinant Proteins Market was valued at USD 5.05 billion in 2023, expected to reach USD 5.80 billion in 2024, and is projected to grow at a CAGR of 14.51%, to USD 13.04 billion by 2030.

Recombinant proteins are engineered proteins that are generated through recombinant DNA technology, enabling the expression of novel proteins in various host systems. This technology is pivotal for therapeutic, diagnostic, and research applications due to its efficiency in producing proteins at a large scale and with high purity. Recombinant proteins are essential in pharmaceuticals for the development of drugs, vaccines, and biologics, as well as in agriculture and food industries for improving plant and animal products. The end-use scope spans medical research, clinical diagnostics, and biotechnological research. The market for recombinant proteins is influenced by growth factors like advancements in bioreactor design, increasing R&D investment, and a rising prevalence of chronic diseases necessitating innovative therapeutics. Opportunities abound in personalized medicine and the growing demand for biopharmaceuticals, as well as expanding applications in gene therapy and regenerative medicine. A vital recommendation is tapping into emerging markets, leveraging cost-efficient production technologies, and forming strategic partnerships for market expansion. However, market growth is challenged by factors such as high production costs, complex regulatory landscapes, and intellectual property issues. The technical complexities involved in protein expression and purification also pose hurdles. To drive innovation, research should focus on optimizing expression systems, developing novel stabilizing techniques for storage and transportation, and utilizing CRISPR-based technologies to enhance protein functionality. Insights suggest a competitive but rapidly evolving market, characterized by continuous technological advancements and a shift towards precision medicine. Companies need to stay abreast of technological trends and regulatory changes, emphasizing sustainability and ethical considerations in their business models to achieve long-term success in the recombinant protein market.

KEY MARKET STATISTICS
Base Year [2023] USD 5.05 billion
Estimated Year [2024] USD 5.80 billion
Forecast Year [2030] USD 13.04 billion
CAGR (%) 14.51%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Recombinant Proteins Market

The Recombinant Proteins Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising focus on personalized medicine & protein therapeutics in the consumers
    • High prevalence of infectious & chronic diseases among geriatric population and children
    • Surging inclination of demand toward biologics and biosimilars proteins
  • Market Restraints
    • Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
  • Market Opportunities
    • Increasing focus on biomarker discovery and surging investments recombinant protein development
    • Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
  • Market Challenges
    • Availability of alternative products and several issues in production

Porter's Five Forces: A Strategic Tool for Navigating the Recombinant Proteins Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Recombinant Proteins Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Recombinant Proteins Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Recombinant Proteins Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Recombinant Proteins Market

A detailed market share analysis in the Recombinant Proteins Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Recombinant Proteins Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Recombinant Proteins Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Recombinant Proteins Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., GeoVax Labs, Inc., Takeda Pharmaceutical Company Limited, LenioBio GmbH, Sino Biological, Inc., Sanofi S.A., Bio-Rad Laboratories, Inc., R&D Systems, Inc. by Bio-Techne Corporation, Proteos, Inc., BPS Bioscience, Inc., Proteintech Group, Inc., BioLegend, Inc. by PerkinElmer, Inc., Thermo Fisher Scientific, Inc., Miltenyi Biotec B.V. & Co. KG, Fortis Life Sciences LLC, Sartorius AG, Bristol-Myers Squibb Company, Creative BioMart Inc., Biogen Inc., Abnova Corporation, Hzymes Biotech, Merck KGaA, Novartis AG, Agilent Technologies, Inc., Lonza Group AG, SK bioscience, Eli Lilly and Company, Johnson & Johnson Services, Inc., Bhat Bio-tech India Private Limited, GenScript Biotech Corporation, Marin Biologic Laboratories, Inc., Meridian Bioscience, Inc. by SD Biosensor Inc., ProMab Biotechnologies, Inc., Abcam PLC, Laurus Labs Limited, Biologics International Corp, Croyez Bioscience Co., Ltd., Enzo Life Sciences, Inc., and Selvita S.A..

Market Segmentation & Coverage

This research report categorizes the Recombinant Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Adhesion Molecules & Receptors, Growth Factors & Chemokines, Immune Response Proteins, Kinase Proteins, Membrane Proteins, Recombinant Metabolic Enzymes, Regulatory Proteins, and Structural Proteins.
  • Based on Services, market is studied across Cloning, Expression, and Purification.
  • Based on End-User, market is studied across Academic Research Institutes, Contract Research Organizations & Contract Manufacturing Organizations, and Pharmaceutical & Biopharmaceutical Companies.
  • Based on Function, market is studied across Diagnostics and Drug Discovery & Development. The Drug Discovery & Development is further studied across Biologics, Cell & Gene Therapy, and Vaccines.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising focus on personalized medicine & protein therapeutics in the consumers
      • 5.1.1.2. High prevalence of infectious & chronic diseases among geriatric population and children
      • 5.1.1.3. Surging inclination of demand toward biologics and biosimilars proteins
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing focus on biomarker discovery and surging investments recombinant protein development
      • 5.1.3.2. Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative products and several issues in production
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Significant use of adhesion molecules & receptors for research purposes
    • 5.2.2. Services: Expression services focus on high yields and compatibility with target protein characteristics
    • 5.2.3. End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies
    • 5.2.4. Function: Potential demand of recombinant proteins for drug discovery & development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Recombinant Proteins Market, by Product

  • 6.1. Introduction
  • 6.2. Adhesion Molecules & Receptors
  • 6.3. Growth Factors & Chemokines
  • 6.4. Immune Response Proteins
  • 6.5. Kinase Proteins
  • 6.6. Membrane Proteins
  • 6.7. Recombinant Metabolic Enzymes
  • 6.8. Regulatory Proteins
  • 6.9. Structural Proteins

7. Recombinant Proteins Market, by Services

  • 7.1. Introduction
  • 7.2. Cloning
  • 7.3. Expression
  • 7.4. Purification

8. Recombinant Proteins Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic Research Institutes
  • 8.3. Contract Research Organizations & Contract Manufacturing Organizations
  • 8.4. Pharmaceutical & Biopharmaceutical Companies

9. Recombinant Proteins Market, by Function

  • 9.1. Introduction
  • 9.2. Diagnostics
  • 9.3. Drug Discovery & Development
    • 9.3.1. Biologics
    • 9.3.2. Cell & Gene Therapy
    • 9.3.3. Vaccines

10. Americas Recombinant Proteins Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Recombinant Proteins Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Recombinant Proteins Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
    • 13.3.2. Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
    • 13.3.3. Fortis Life Sciences acquires International Point of Care
    • 13.3.4. Curia Expands Cell Line Development Offering with CHOZN Platform
    • 13.3.5. Future Fields raises USD 11.2 million to scale up fruit flies for recombinant protein production
    • 13.3.6. Merck's Biodevelopment Centre Expansion, Martillac, France
    • 13.3.7. Shenandoah Biotechnology Introduces Expanded Range of CTGrade Recombinant Proteins Manufactured Following cGMP Practices
    • 13.3.8. Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins
    • 13.3.9. Thermo Fisher Scientific Completes Acquisition of PeproTech, engaged in Recombinant Proteins

Companies Mentioned

  • 1. Takara Bio Inc.
  • 2. GeoVax Labs, Inc.
  • 3. Takeda Pharmaceutical Company Limited
  • 4. LenioBio GmbH
  • 5. Sino Biological, Inc.
  • 6. Sanofi S.A.
  • 7. Bio-Rad Laboratories, Inc.
  • 8. R&D Systems, Inc. by Bio-Techne Corporation
  • 9. Proteos, Inc.
  • 10. BPS Bioscience, Inc.
  • 11. Proteintech Group, Inc.
  • 12. BioLegend, Inc. by PerkinElmer, Inc.
  • 13. Thermo Fisher Scientific, Inc.
  • 14. Miltenyi Biotec B.V. & Co. KG
  • 15. Fortis Life Sciences LLC
  • 16. Sartorius AG
  • 17. Bristol-Myers Squibb Company
  • 18. Creative BioMart Inc.
  • 19. Biogen Inc.
  • 20. Abnova Corporation
  • 21. Hzymes Biotech
  • 22. Merck KGaA
  • 23. Novartis AG
  • 24. Agilent Technologies, Inc.
  • 25. Lonza Group AG
  • 26. SK bioscience
  • 27. Eli Lilly and Company
  • 28. Johnson & Johnson Services, Inc.
  • 29. Bhat Bio-tech India Private Limited
  • 30. GenScript Biotech Corporation
  • 31. Marin Biologic Laboratories, Inc.
  • 32. Meridian Bioscience, Inc. by SD Biosensor Inc.
  • 33. ProMab Biotechnologies, Inc.
  • 34. Abcam PLC
  • 35. Laurus Labs Limited
  • 36. Biologics International Corp
  • 37. Croyez Bioscience Co., Ltd.
  • 38. Enzo Life Sciences, Inc.
  • 39. Selvita S.A.

LIST OF FIGURES

  • FIGURE 1. RECOMBINANT PROTEINS MARKET RESEARCH PROCESS
  • FIGURE 2. RECOMBINANT PROTEINS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RECOMBINANT PROTEINS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RECOMBINANT PROTEINS MARKET DYNAMICS
  • TABLE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ADHESION MOLECULES & RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS & CHEMOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMMUNE RESPONSE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY KINASE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MEMBRANE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RECOMBINANT METABOLIC ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGULATORY PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY STRUCTURAL PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CLONING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 240. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023